CIK: 0001766721 · Show all filings
Period: Q3 2022 (← Previous) (Next →)
Filing Date: Nov 3, 2022
Total Value ($000): $150,591 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | 6,068,125 | $60,317 | 40.1% | $40.43 | -74.3% | COM | 10806X102 |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | 1,025,000 | $24,631 | 16.4% | $10.24 | +119.1% | COM | 87164F105 |
| — | Verona Pharma plc (VRNA) | 1,332,485 | $13,618 | 9.0% | $7.38 | — | SPONSORED ADS | 925050106 |
| GLUE | Monte Rosa Therapeutics Inc. (GLUE) | 1,472,331 | $12,029 | 8.0% | $20.37 | -54.9% | COM | 61225M102 |
| ACRS | Aclaris Theraputics Inc. (ACRS) | 634,455 | $9,986 | 6.6% | $10.31 | +52.8% | COM | 00461U105 |
| BMEA | Biomea Fusion Inc. (BMEA) | 798,757 | $7,812 | 5.2% | $17.65 | -35.0% | COM | 09077A106 |
| NUVB | Nuvation Bio Inc. (NUVB) | 2,541,009 | $5,692 | 3.8% | $11.18 | -74.5% | COM CL A | 67080N101 |
| — | Poseida Therapeutics Inc. (PSTX) | 1,043,267 | $3,683 | 2.4% | $8.87 | — | COM | 73730P108 |
| — | Elevation Oncology Inc. (ELEV) | 2,834,910 | $3,203 | 2.1% | $13.57 | — | COM | 28623U101 |
| — | Reneo Pharmaceuticals Inc. (RPHM) | 886,075 | $2,968 | 2.0% | $9.33 | — | COM | 75974E103 |
| — | Spruce Biosciences, Inc. (SPRB) | 1,205,511 | $1,652 | 1.1% | $24.31 | — | COM | 85209E109 |
| — | Viracta Therapeutics Inc. (VIRX) | 288,571 | $1,232 | 0.8% | $11.34 | — | COM | 92765F108 |
| — | Marker Therapeutics, Inc. (MRKR) | 3,142,857 | $1,163 | 0.8% | $4.35 | — | COM | 57055L107 |
| — | Aeglea Biotherapeutics Inc. (AGLE) | 1,691,151 | $890 | 0.6% | $8.00 | — | COM | 00773J103 |
| — | AVROBIO, Inc. (AVRO) | 1,009,779 | $646 | 0.4% | $16.72 | — | COM | 05455M100 |
| — | Atreca Inc. (BCEL) | 387,653 | $609 | 0.4% | $18.84 | — | CL A COM | 04965G109 |
| — | Talaris Therapeutics Inc. (TALS) | 175,000 | $460 | 0.3% | $14.69 | — | COM | 87410C104 |